BackgroundChitosan and its derivates are widely used for biomedical application due to antioxidative, anti-inflammatory, antimicrobial and tissue repair induced properties. Chitosan-based materials also used as a haemostatic agent but influence of different molecular weight and concentration of chitosan on biological response of blood cells is still not clear.The aim of this research was to evaluate interaction between human blood cells and various forms of chitosan-based materials with different molecular weight and chitosan concentration and prove their effectiveness on in-vivo model.MethodsWe used chitosan with molecular weight 200, 500 and 700 kDa and deacetylation rate 80-82 %. For chitosan impregnation of gauze chitosan solutions in 1 % acetic acid with different concentrations (1, 2, 3, 5 %) were used. We used scanning electron microscopy to obtain information about chitosan distribution on cotton surface; Erythrocyte agglutination test and Complete blood count test – for evaluation of interaction between blood cells and chitosan-based materials with different compound. In-vivo studies was performed in 20 Wistar rats to evaluate effectiveness of new dressing.ResultsOur data shown that chitosan can bind erythrocytes in concentration-depend manner that does not depend on its molecular weight. In addition, chitosan-based materials affect selectively human blood cells. Composition of chitosan with cotton materials does not change erythrocyte shape and does not cause agglutination.ConclusionsСotton-chitosan materials have higher adhesive properties to platelets that depend on molecular weight and concentration of chitosan. These materials also change platelets’ shape that probable is one of the most important mechanisms of haemostatic effect. In-vivo studies have shown high effectiveness of 2 % 200 kDa chitosan for stop bleeding from arteries of large diameter.

No abstract

No abstract

Background:The aim of the study was to determine the effect of gene polymorphisms Arg389Gly ADRβ 1 gene and T393C gene GNAS1 on the level of heart rate (HR), systolic and diastolic blood pressure (SBP and DBP) (p <0,001). During the analysis of polymorphism T393C of GNAS1 gene only in patients from III subgroup was found a higher heart rate in patients with T393T genotype relatively to C393C genotype, but this difference was not statistically significant (p =0,191

Наведено результати визначення 10 поліморфізмів генів системи матриксного Gla-протеїну (ген MGP-T-138 →С (rs1800802), G-7 →A (rs1800801), Thr 83 →Ala (rs4236); ген VDR-FokI (rs2228570), BsmI (rs1544410), ApaI (rs7975232), TaqI (rs731236), ген GGCX-Arg 325 →Gln (rs699664), ген VKORС1-T 2255 →C (rs2359612), ген BMP-2-Ser 37 →Ala (rs2273073)) у 170 хворих з ішемічним атеротромботичним інсультом (ІАТІ) і 124 здорових індивідуумів (контрольна група). Встановлено, що існує зв'язок між ІАТІ і поліморфними варіантами генів MGP (G-7 →A) та VKORC1 (Т 2255 →С). Ризик розвитку ІАТІ у носіїв мінорного алеля A/A (G-7 →A-поліморфізм) у 2,6 вищий, ніж у носіїв основного алеля (G/A+G/G), а у осіб з генотипом С/С (Т 2255 →С-поліморфізм) у 2,2 раза більший, ніж у гомозигот за основним алелем. Збіг у пацієнтів генотипів T/C і G/G, C/C і G/A, а також генотипу A/A (G-7 →Aполіморфізм) із будь-яким з генотипів за Т 2255 →С-поліморфізмом збільшує ризик розвитку ІАТІ.